Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- MHLW to Consider Conditional Approval for Shionogi COVID Pill: Minister
February 9, 2022
- MHLW Ordered Label Revisions for Emergency Contraceptive Levonorgestrel
February 8, 2022
- Japan Mulls Early Conditional Approval for Shionogi’s COVID Pill
February 8, 2022
- Japan to Speed Up Boosters to “1 Million Doses per Day” ASAP: PM
February 7, 2022
- Lilly’s Retevmo Clears PAFSC for Thyroid Cancer; Lenvima/Keytruda to Get RCC Indication
February 7, 2022
- Japan Receiving 90,000 Further Courses of MSD COVID-19 Pill Earlier than Scheduled
February 7, 2022
- FY2022 Drug Price Revision Rate at -6.69% on Pharma Spending Basis
February 4, 2022
- Pfizer’s COVID-19 Pill Up for PAFSC Review on Feb. 10
February 4, 2022
- 9 Drugs/6 APIs for Fertility Treatment to Be Listed in April; Generics Listing in June at the Earliest: Chuikyo
February 3, 2022
- Govt Panel Proposes Enhanced Pharma Supply Chain through Economic Security Bill
February 2, 2022
- MHLW Clarifies Position on Investigational Drug Info; No Generic Names Allowed on Companies’ Clinical Trial Websites
February 2, 2022
- DPO Opted Not to Apply 80% Pricing Rule for Vynmac for Clinical Benefits: Minutes
February 2, 2022
- MHLW OKs 115 More COVID-19 Vaccine Health Damage Claims
February 1, 2022
- Japan Finalizes Deal for Pfizer’s COVID-19 Pills, Eyes Approval by Mid-February
February 1, 2022
- Japan Won’t Give 3rd-Shot Approval for Shionogi’s Jab with Booster Trial Alone
February 1, 2022
- MHLW Panel Holds Off Decision on Bayer’s CKD Med Kerendia
January 31, 2022
- Veklury Use in Mild COVID-19 Could Be Considered: MHLW
January 31, 2022
- MSD Moves Up Supply of 50000 Courses of Lagevrio to Japan
January 31, 2022
- Cost-Effectiveness Analysis Temporarily Halted for Zolgensma to Collect Long-Term Data
January 31, 2022
- MHLW Panel OKs Mix-and-Match HPV Vaccines in “Catch-Up” Program
January 31, 2022
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…